<DOC>
	<DOCNO>NCT02215993</DOCNO>
	<brief_summary>Introduction : Platelet aggregation play important role ischemic complication patient undergo percutaneous coronary intervention ( PCI ) . The addition clopidogrel , second antiplatelet agent , acetylsalicylic acid ( ASA ) effective reduce major cardiovascular event patient acute coronary syndrome ( ACS ) . However , approximately 30 % ACS patient resistant clopidogrel , represent population medically vulnerable high risk major cardiovascular event , include myocardial infarction ( MI ) , stent thrombosis death . In randomized trial TRITON , prasugrel compare clopidogrel effective significantly reduce rate MI ( 7.4 % vs. 9.4 % ) stent thrombosis ( 2.4 % vs .1,1 % ) patient ACS , however , patient treat prasugrel show high rate bleed ( 2.4 vs. 1.8 % ) difference mortality . Upon analysis subgroup recommend use patient history stroke old 75 year weigh less 60 kg . The late class inhibitor P2Y12 receptor cyclopentyl-triazolopyrimidines represent ticagrelor . Unlike thienopyridines , ticagrelor interacts platelet receptor reversible way begin peak action faster . The efficacy safety ticagrelor evaluate study PLATO , 18.624 patient ACS randomize receive clopidogrel ( 75mg/day , load dose 300 600mg ) ticagrelor ( 90mg 2x/day load dose 180mg ) The primary combined endpoint ( mortality vascular cause , MI stroke ) 12 month significantly low ticagrelor ( 9.8 % vs. 11.7 % ) . There significant difference rate major bleed group . Moreover , isolated analysis rate MI , vascular mortality mortality cause show statistically significant reduction ticagrelor user . In study , main adverse effect dyspnea bradycardia . The assessment platelet reactivity may allow individualization antiplatelet therapy . However , simply increase dose clopidogrel patient persist high platelet reactivity able reduce combine endpoint cardiovascular death , nonfatal myocardial infarction stent thrombosis six month . In population patient stable coronary artery disease , substitution clopidogrel ticagrelor show rapid persistent decrease platelet aggregation measure different laboratory method . However , patient ACS subject PCI , assessment platelet aggregation replacement clopidogrel prasugrel ticagrelor still require evidence . Objectives : To evaluate platelet response ticagrelor prasugrel ACS patient ST-segment elevation submit thrombolysis . To evaluate security follow 30 day . Methods : The study prospective , randomize , single-center ( São Paulo Hospital - Federal University São Paulo ) , single-blind . The investigator select 50 patient admitted ACS ST-segment elevation submit thrombolysis underwent cardiac catheterization 3 24 hour case reperfusion immediately rescue angioplasty . Blood sample analysis platelet aggregation system VerifyNow ® , shall obtain immediately procedure patient clopidogrel least seven day maintenance dose 75mg 8 6 hour dose 300mg 600mg respectively . Patients randomize 1:1 ratio receive ticagrelor dose 180mg maintain dose 90 mg twice day thirty day prasugrel dose 60mg maintain thirty day daily dose 10mg . A new blood sample analysis platelet aggregation repeat 2 , 6 24 hour . The demographic clinical data population collect specific form store database later analysis</brief_summary>
	<brief_title>Sampling P2Y12 Receptor Inhibition With Prasugrel Ticagrelor Patients Submitted Thrombolysis</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>less 75 year sign consent form Acute coronary syndrome STsegment elevation submit thrombolysis use IIbIIIa inhibitor le 60 kg history stroke Patients sick sinus syndrome , atrioventricular block second third degree , protect pacemaker Chronic obstructive pulmonary disease Asthma Heart failure class III / IV renal replacement therapy Use inducer ( carbamazepine , phenytoin , phenobarbital , rifampicin dexamethasone ) inhibitor ( ketoconazole , itraconazole , ritonavir , saquinavir , clarithromycin ) potent enzyme PYP3A</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>Prasugrel</keyword>
	<keyword>VerifyNow</keyword>
	<keyword>Acute coronary syndrome</keyword>
</DOC>